Newsbenzinga
Opus Genetics Announces Completion Of Dosing In Higher-Dose Cohort 2 Of Phase 1/2 OPGx-BEST1 Trial; Expects Topline Data In Q1 2027
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…